Menu
Enrolling by invitation NCT07150221

MDR Vivacit-E Elevated Study

Observational Osteoarthritis (OA) of the Hip Avascular Necrosis of Bone of Hip Protrusio Acetabuli Traumatic Arthropathy-Hip

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Vivacit-E Elevated Liners.
Who it may be relevant to
Registry conditions: Osteoarthritis (OA) of the Hip, Avascular Necrosis of Bone of Hip, Protrusio Acetabuli, Traumatic Arthropathy-Hip. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Post-Market Clinical Follow-Up Study of the Vivacit-E Vitamin E Highly Crosslinked Polyethylene HXLPE Elevated Liners in Primary THA- A Retrospective Enrollment/Prospective Follow-Up Study

Overview

The main objective of this study is to confirm long-term safety, performance, and clinical benefits of the Vivacit-E Vitamin E HXLPE Elevated Liners when used in primary total hip arthroplasty.

Interventions

  • Device Vivacit-E Elevated Liners
    Primary total hip arthroplasty

Primary outcome measures

  • Survival of the Implant System via Adverse Events [Time frame: 10 years]
Secondary outcome measures (2)
  • Pain and functional performance measured by the Oxford Hip Score [Time frame: 10 years]
  • Subject quality-of-life measured by the EQ-5D-5L [Time frame: 10 Years]

Eligibility criteria

Inclusion criteria

  • Patient was 18 years of age or older and skeletally mature at the time of surgery
  • Patient qualified for and underwent surgical procedure with a Vivacit-E Vitamin E HXLPE Elevated Liner to treat one of the following indications in primary THA:
  • Noninflammatory degenerative joint disease including osteoarthritis and avascular necrosis
  • Protrusio acetabuli
  • Traumatic arthritis
  • Slipped capital epiphysis
  • Fused hip
  • Fracture of the pelvis
  • Diastrophic variant
  • Patient underwent surgical procedure 10 years (+ no maximum/- 182 days) prior to date of study consent
  • Patient is will and able to sign IRB approved Informed Consent Form or provide verbal consent

Exclusion criteria

  • Off label use or not according to the approved IFU at the time of surgery
  • Patient presented with any of the following at the time of the surgical procedure:
  • Osteoradionecrosis
  • Neuromuscular compromise, vascular deficiency or other conditions in the affected limb that may lead to inadequate skeletal fixation
  • Systemic or local infection
  • Revision procedure where other treatment or devices have failed\*
  • Patient has a psychiatric illness or cognitive deficit that will not allow for proper informed consent
  • Uncooperative patient or patient with neurologic disorders who is incapable or unwilling to follow directions
  • For the purpose of this clinical study; a revision procedure refers to a procedure in which the prior procedure on the ipsilateral hip utilized a similar approach (i.e., primary total hip arthoplasty)

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

United States · 1 center
  • South Bend Orthopaedics — South Bend

Identifiers

NCT: NCT07150221 · MDRG2017-89MS-106H

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗